超越骨髓:髓外多发性骨髓瘤肿瘤的综合二代测序启示
该研究对14例髓外多发性骨髓瘤(EMM)肿瘤进行迄今最全面的二代测序分析,发现79%的EMM样本共现1q21获得/扩增与MAPK通路突变;在CoMMpass数据集中,诊断时KRAS突变合并1q21获得/扩增的患者发生EMM风险显著更高(HR=2.4,p=0.011)。研究还揭示CXCR4下调、治疗靶点表达降低及EZH2和CD70上调,并首次报道EMM肿瘤微环境及纵向分子变化。
要点
- 79%的EMM样本共现1q21获得/扩增与MAPK通路突变。
- 诊断时KRAS突变合并1q21获得/扩增者EMM风险更高(HR=2.4,p=0.011)。
- EMM中CXCR4下调、CD38/SLAMF7/GPRC5D/FCRH5表达降低,EZH2和CD70上调。
核心结论
- EMM肿瘤中1q21获得/扩增与MAPK通路突变共现提示其为EMM发展的关键突变事件。
- 诊断时KRAS突变合并1q21获得/扩增与EMM发生风险显著升高相关(HR=2.4,p=0.011)。
- EMM中CXCR4下调及治疗靶点表达降低可能解释免疫治疗疗效减弱,EZH2和CD70上调为潜在未来治疗选择。
研究设计与样本
- 对14例EMM肿瘤进行二代测序分析,为迄今最全面的EMM肿瘤二代测序分析。
- 利用大型CoMMpass数据集分析诊断时突变与EMM发生风险。
- 使用单细胞测序分析EMM肿瘤微环境。
- 纵向研究比较诊断至EMM复发期间的分子变化。
主要发现
- 79%的EMM样本共现1q21获得/扩增与MAPK通路突变。
- 诊断时KRAS突变合并1q21获得/扩增的患者EMM发生风险显著更高(HR=2.4,p=0.011)。
- EMM中CXCR4下调、细胞增殖增强,治疗靶点CD38、SLAMF7、GPRC5D、FCRH5表达降低。
- EMM中EZH2和CD70显著上调。
- EMM肿瘤微环境中CD8+ T细胞和NK细胞为主要免疫效应细胞。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Extramedullary multiple myeloma (EMM) is an aggressive form of multiple myeloma (MM). This study represents the most comprehensive next-generation sequencing analysis of EMM tumors (N = 14) to date, uncovering key molecular features and describing the tumor microenvironment. We observed the co-occurrence of 1q21 gain/amplification and MAPK pathway mutations in 79% of EMM samples, suggesting that these are crucial mutational events in EMM development. We also demonstrated that patients with mutated KRAS and 1q21 gain/amplification at the time of diagnosis have a significantly higher risk of EMM development (HR = 2.4, p = 0.011) using data from a large CoMMpass dataset. We identified downregulation of CXCR4 and enhanced cell proliferation, along with reduced expression of therapeutic targets (CD38, SLAMF7, GPRC5D, FCRH5), potentially explaining diminished efficacy of immunotherapy. Conversely, we identified significantly upregulated EZH2 and CD70 as potential future therapeutic options. For the first time, we report on the tumor microenvironment of EMM, revealing CD8+ T cells and NK cells as predominant immune effector cells using single-cell sequencing. Finally, this is the first longitudinal study in EMM revealing the molecular changes from the time of diagnosis to EMM relapse.
引用
- Jelinek T, Zihala D, Sevcikova T, et al. Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors. Leukemia. 2024. PMID: 38493239. doi:10.1038/s41375-024-02206-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。